Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (211-220 of 232) with videos related to

Pageof 24
Sort By:
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|August 1, 1982
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB studyJ Yates, O Glidewell, P Wiernik, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Leukemia|June 1, 2017
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosisF Passamonti, T Giorgino, B Mora, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 24

Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|August 1, 1982
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB studyJ Yates, O Glidewell, P Wiernik, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Leukemia|June 1, 2017
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosisF Passamonti, T Giorgino, B Mora, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 24